news banner 2107 2

News

Print

Phylis Mzanga Attends Clinical Trial Management Workshop at Strathmore University, Nairobi, Kenya

on .

Phylis MzangaProject Coordinator for Malaria Epidemiology Research Group Phylis Mzanga recently secured a scholarship to attend a workshop in clinical trial management for study coordinators in low income countries.


The workshop was organised by the Strathmore University and Faculty for Capacity Development (FCD) with funding from different partners including TDR- WHO and International AIDS Vaccine Initiative (IAVI). The event took place at Strathmore University, Nairobi, Kenya. The aim was to equip study coordinators to take extra responsibilities to support Principal Investigators and study teams.


From Malawi, Phylis was joined by Getrude Mwase Banda the Deputy Clinical Manager from Malawi-Liverpool-Wellcome Trust Clinical Research Programme (MLW). During the workshop, Phylis learnt a lot from the interaction with a diverse group of study coordinators from across Africa and experienced faculty members from all over the world.


“I am very thankful to the FCD, Strathmore University, TDR- WHO and International AIDS Vaccine Initiative (IAVI) for bringing together study coordinators across Africa to share experiences and build a working network to improve management of clinical trials in low Income countries. I feel am now ready to support fellow coordinators, Principal Investigators and study teams at MLW with mentorship, Clinical trial implementation and training,” said Phylis.

 

Print

Wider use of rotavirus vaccine urged after 'potent' success of Malawi trial

on .

Dramatic fall in infant deaths prompts calls for national immunisation programmes to incorporate treatment

Rotavirus Vaccine Baby

A baby in Ghana receives the rotavirus vaccine. Photograph: Courtesy of Gavi


A rotavirus vaccine introduced in rural Malawi has reduced deaths from infant diarrhoea by more than a third, proving for the first time that a major intervention in a low-income country can be highly effective.


The findings, published in the Lancet Global Health, are likely to add further weight to calls by global health experts for rotavirus vaccine to be included in all national immunisation programmes.


“These findings are very, very encouraging indeed,” said Malawi’s chief of health services, Dr Charles Mwansambo.
“Rotavirus is a major problem in Malawi, but since the introduction of the vaccine we’ve seen remarkable drops in hospital admissions, proving that the vaccine is a worthwhile investment.”


Malawi introduced the monovalent rotavirus vaccine (RV1) in October 2012. For four years, scientists from the University of Liverpool, University College London, Johns Hopkins University and partners in Malawi tracked 48,672 infants born after the introduction of the vaccine. The monitoring, which covered more than 1,800 villages, involved documenting the childrens’ vaccination status and recording whether they survived beyond their first birthday.


Infants who received the vaccine had a 34% lower risk of dying from diarrhoea, researchers found – an impact similar to that seen in middle-income countries.

“Rotavirus remains a leading cause of severe diarrhoea and death among infants and young children in many countries in Africa and Asia,” said Professor Nigel Cunliffe from the University of Liverpool’s centre for global vaccine research, who led the study.


“Our findings strongly advocate the incorporation of rotavirus vaccine into the childhood immunisation programmes of countries with high rates of diarrhoea deaths, and support continued use in such countries where a vaccine has been introduced.”


Globally, rotavirus is the leading cause of severe diarrhoea, which claims the lives of an estimated 1,300 children daily, mainly in sub-Saharan Africa. Highly contagious, particularly among babies and young children, rotavirus can be spread by contaminated hands, objects such as toys and surfaces, and water and food. Diarrhoea is the second largest cause of death among infants and children worldwide, primarily in low-income countries, where access to clean water and sanitation is limited.


Although children in the world’s poorest countries account for 82% of rotavirus deaths, vaccines make a significant difference. In Mexico, diarrhoeal deaths among children under five declined by as much as 50%after rotavirus vaccines were introduced.


Yet, of the 10 countries with the greatest number of rotavirus-related deaths, only six – Afghanistan, Angola, Ethiopia, India, Kenya and Pakistan – have introduced national rotavirus vaccines or initiated phased introductions, according to the Rota Council.


Through Gavi, the global vaccine alliance, a number of lower-income countries have been able to implement the inoculation nationally. But vaccine support is withdrawn as GDP increases, which has left a number of high-burden countries to choose between continued administration of the vaccine or devoting funds to other key areas.
Researchers believe the data from Malawi is likely to create a positive tipping point, given the significant reduction both in deaths from rotavirus infection and overall deaths from diarrhoea.


“This trial provides potent evidence that, because of the many different effects of the vaccine, it is a worthy public health intervention,” said UCL’s Professor Robert Heyderman, who worked on the study.


“The key thing is that when a child gets diarrhoea, it leaves the child debilitated to other illnesses, such as malaria or pneumonia or something else, and that has a knock-on effect which can translate to poor performance in education or, ultimately, death. Although 34% doesn’t sound large, it’s a large impact on all infant diarrhoeal deaths. When we assessed the direct effect on rotavirus alone, the impact was very big – around 64%.”

Rotavirus Vaccine Mother
A mother shows her baby’s vaccination certificate in Rumphi, northern Malawi. Photograph: Danita Delimont/Alamy


The vaccine can also help to improve nutrition, said Dr Carina King, one of the report’s lead authors and a senior research associate at UCL’s institute for global health.


“Repeated episodes of diarrhoea can contribute to a child becoming malnourished over time. Stopping that cycle allows the child to be better nourished and develop greater immunity, preventing the child from getting sick and dying from something else,” said King.


By the end of the study, researchers noted 92% coverage across Malawi for the rotavirus RV1 vaccine – a very high turnout for one of the poorest nations in the world, said Heyderman.


“We have three regions in Malawi, and 28 district hospitals, each of which acts as a centre for immunisations, so we try as much as we can to get into the remotest parts of the country and get the vaccine to as many people as possible,” said Mwansambo.


“For those countries that haven’t introduced the rotavirus vaccination, I don’t know what they’re waiting for. We know that it’s effective and that our children deserve better. They need it.”

Print

Marc Henrion Presents at the Joint Statistical Meetings

on .

Marc JSM2018 1On 30th July, the head of the Statistical Support Unit (SSU) at MLW, Dr. Marc Henrion, presented at a major international statistics conference, the Joint Statistical Meetings (JSM) in Vancouver, Canada.

The talk focused on extending a particular class of models, latent Markov models (LMMs) to be able to estimate sensitivities and specificities of four new molecular diagnostic tests for Salmonella that have been validated by Angeziwa Chirambo and Dr. Tonney Nyirenda from the Salmonella and Enteric Disease group. The reference diagnostic tests for Salmonella, stool culture, was also assessed by the LMMs.

LMMs are commonly used to analyse longitudinal data from multiple diagnostic tests. LMMs consist of a structural model for the latent infection states, defining probabilities for initial state and transmission between states, and a measurement model for the observed test results, defining the item response probabilities and thus test sensitivities and specificities. LMMs typically assume that tests are independent conditional on the latent infection state. This is likely to be violated for tests using similar technologies (as is the case here: four tests using the same PCR technology and two-by-two the molecular tests use the same primers).

Marc presented how the conditional independence assumption can be relaxed by introducing random subject-level. Using simulation data, Marc illustrated the benefits of the mixed LMMs. The talk concluded with an analysis of longitudinal data from four molecular PCR tests and a stool culture test from patients in Blantyre, Malawi. To assess the tests' performances, both basic and mixed LMMs were fitted. A PCR assay using primers from the TTR gene achieves the best sensitivity / specificity trade-off.